Evox Therapeutics Ltd, an Oxford-based biotechnology company, has named Dr David Lowe as its new vice president of research, it was reported on Tuesday.
In the new role, Lowe will be managing the research group with the aim of advancing the company's pipeline and continuing the development of its proprietary exosome platform.
Dr Lowe has more than 20 years of biotech and large pharma R&D experience in advancing protein and antibody-based therapeutics and exploring novel therapeutic modalities such as gene therapy, mRNA therapeutics and exosomes. He has spent more than 12 years at AstraZeneca, most recently as senior director of Biologics Engineering. He has spent around 10 years at Cambridge Antibody Technology. He was also a principal investigator on a USD17m grant from the Defense Advanced Research Projects Agency.
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer